ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Currently, molecular target therapies that focus on the ABL1 tyrosine kinase, particularly the application of tyrosine kinase inhibitors, have significantly enhanced the life expectancy of patients with CML and markedly improved their quality of life (5, 6).